Skip to content

LSD: all studies

Page 131 of 282: studies 1,301 to 1,310 of 2,815, newest first. Back to the LSD overview

Research

The epistemic innocence of psychedelic states.

Consciousness and Cognition 2016 Chris Letheby 68 citations

One recent development in epistemology, the philosophical study of knowledge, is the notion of 'epistemic innocence' introduced by Bortolotti and colleagues. This concept expresses the idea that certain suboptimal cognitive processes may nonetheless have epistemic (knowledge-related) benefits. The idea that delusion or confabulation may have psychological benefits is familiar enough. What is...

Acid Brothers: Henry Beecher, Timothy Leary, and the psychedelic of the century.

Perspectives in biology and medicine 2016 Jonathan D Moreno 15 citations

Henry Knowles Beecher, an icon of human research ethics, and Timothy Francis Leary, a guru of the counterculture, are bound together in history by the synthetic hallucinogen lysergic acid diethylamide (LSD). Both were associated with Harvard University during a critical period in their careers and of drastic social change. To all appearances the first was a paragon of the establishment and a...

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Journal of Psychoactive Drugs October 20, 2015 Emmanuelle A. D. Schindler, Christopher Gottschalk, Marsha J. Weil et al. 104 citations

Cluster headache is one of the most debilitating pain syndromes. A significant number of patients are refractory to conventional therapies. The Clusterbusters.org medication use survey sought to characterize the effects of both conventional and alternative medications used in cluster headache. Participants were recruited from cluster headache websites and headache clinics. The final analysis...

Neuroreceptor activation by vibration-assisted tunneling.

Scientific Reports April 24, 2015 Ross D Hoehn, David Nichols, Hartmut Neven et al.

G protein-coupled receptors (GPCRs) constitute a large family of receptor proteins that sense molecular signals on the exterior of a cell and activate signal transduction pathways within the cell. Modeling how an agonist activates such a receptor is fundamental for an understanding of a wide variety of physiological processes and it is of tremendous value for pharmacology and drug design....

The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey

Cephalalgia April 22, 2015 Cherubino Di Lorenzo, Gianluca Coppola, Giorgio Di Lorenzo et al. 40 citations

Background Cluster headache (CH) patients often receive unsatisfactory treatment and may explore illicit substances as alternatives. We aimed to explore this use of illicit drugs for CH treatment. Methods We invited CH patients from an Internet-based self-help group to complete a questionnaire regarding their therapeutic use of illicit substances. Results Of the 54 respondents, 29 were...

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of Psychopharmacology March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

Psychedelics not linked to mental health problems or suicidal behavior: A population study

Journal of Psychopharmacology March 1, 2015 Pål-ørjan Johansen, Teri Suzanne Krebs 300 citations

A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental...

Drug models of schizophrenia.

Therapeutic Advances in Psychopharmacology February 1, 2015 Hannah Steeds, Robin Carhart-Harris, James Stone 132 citations

Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients....

Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases.

European Neuropsychopharmacology August 2014 Ruud P. W. Litjens, Tibor M Brunt, Gerard-Jan Alderliefste et al.

Hallucinogen persisting perception disorder (HPPD) is a drug-induced condition associated with inaccurate visual representations. Since the underlying mechanism(s) are largely unknown, this review aims to uncover aspects underlying its etiology. Available evidence on HPPD and drug-related altered visual processing was reviewed and the majority of HPPD cases were attributed to drugs with...

Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.

Therapeutic Advances in Psychopharmacology August 1, 2014 David Baumeister, Georgina Barnes, Giovanni Giaroli et al.

Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on...